8-K: Plus Therapeutics Sets Annual Meeting, Updates Deadlines
Annual Meeting Announcement
Plus Therapeutics, Inc. announced the date for its 2026 Annual Meeting of Stockholders and revised deadlines for shareholder proposals and director nominations.
Summary
- The 2026 Annual Meeting of Stockholders will be held virtually on Thursday, May 14, 2026, at 9:00 a.m. Eastern Time.
- The record date for stockholders entitled to notice of, and to vote at, the 2026 Annual Meeting is March 18, 2026.
- Due to the 2026 Annual Meeting being scheduled more than 30 days before the anniversary of the 2025 Annual Meeting, previously set deadlines for stockholder proposals and director nominations are no longer applicable.
- New deadlines for stockholder proposals submitted pursuant to Rule 14a-8 and for nominations/proposals under the Company's Bylaws are March 22, 2026.
- Stockholders intending to solicit proxies in support of director nominees must provide notice as required by Rule 14a-19 of the Exchange Act no later than March 22, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, administrative update regarding standard corporate governance procedures, with no direct positive or negative financial implications.
Future Outlook
The company plans to hold its 2026 Annual Meeting of Stockholders virtually on May 14, 2026, and has established new deadlines for shareholder proposals and director nominations in preparation for this event.
Industry Context
StockSavvy.ai notes that the announcement of annual meeting dates and associated deadlines is a standard corporate governance practice, ensuring transparency and providing shareholders with the necessary information to participate in company affairs. The shift to a virtual meeting format aligns with broader industry trends towards digital engagement and cost efficiency.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Annual Meeting Date | The 2026 Annual Meeting of Stockholders is set for May 14, 2026, which is more than 30 days before the anniversary of the 2025 meeting. | May 14, 2026 | Requires revision of shareholder proposal and nomination deadlines to comply with SEC rules and company bylaws. |
| Shareholder Proposal Deadlines | Revised deadlines for stockholder proposals under Rule 14a-8 and advance notice provisions of the Bylaws are now March 22, 2026. | March 22, 2026 | Provides shareholders with updated timelines for submitting proposals and nominations for the upcoming annual meeting. |
| Universal Proxy Rule Compliance | Notice for soliciting proxies in support of director nominees (Rule 14a-19) must be provided by March 22, 2026. | March 22, 2026 | Ensures compliance with universal proxy rules for shareholders intending to nominate directors. |
Stakeholder Impact
- Shareholders: Impacted by the new meeting date, record date, and revised deadlines for submitting proposals and nominations, affecting their ability to participate in corporate governance.
Next Steps
- The Company will begin to print and send its proxy materials for the 2026 Annual Meeting.
- Stockholders will submit proposals or nominations by the revised deadline of March 22, 2026.
- The 2026 Annual Meeting will be held virtually on May 14, 2026.
Key Dates
| Date | Description |
|---|---|
| 2025 | Year of the previous Annual Meeting of Stockholders, referenced for anniversary calculation. |
| March 11, 2026 | Date the Board of Directors determined the 2026 Annual Meeting date and revised deadlines. |
| March 12, 2026 | Date the 8-K report was signed. |
| March 18, 2026 | Record date for stockholders entitled to notice of, and to vote at, the 2026 Annual Meeting. |
| March 22, 2026 | Deadline for stockholder proposals under Rule 14a-8, advance notice nominations/proposals under Bylaws, and Rule 14a-19 notices for director nominees. |
| May 14, 2026 | Date of the 2026 Annual Meeting of Stockholders. |
Keywords
Plus Therapeutics, PSTV, Annual Meeting, Shareholder Meeting, Corporate Governance, SEC Filing, Stockholder Proposals, Director Nominations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.